Kiniksa Pharmaceuticals International (KNSA) Current Deferred Revenue (2022 - 2024)

Kiniksa Pharmaceuticals International has reported Current Deferred Revenue for 3 years, with the latest figure at $31.8 million in Q4 2024.

• For the quarter ending Q4 2024, Current Deferred Revenue rose 10261.89% year-over-year to $31.8 million; the trailing twelve-month figure through Dec 2024 stood at $31.8 million (up 10261.89% YoY), and the FY2024 full-year result was $31.8 million, up 10261.89% from the prior year.
• Current Deferred Revenue for Q4 2024 stood at $31.8 million, up from $12000.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $31.8 million in Q4 2024, with the low at $12000.0 in Q2 2024.
• Historically, Current Deferred Revenue has averaged $7.8 million across 3 years, with a median of $4.7 million in 2023.
• The largest YoY upside for Current Deferred Revenue was 10261.89% in 2024 against a maximum downside of 99.74% in 2024.
• Kiniksa Pharmaceuticals International's Current Deferred Revenue stood at $12.0 million in 2022, then tumbled by 97.44% to $307000.0 in 2023, then jumped by 10261.89% to $31.8 million in 2024.
• The last three Current Deferred Revenue figures came in at $31.8 million (Q4 2024), $12000.0 (Q2 2024), and $156000.0 (Q1 2024), per Business Quant data.